A psilocin drug passes its first Phase 3, the FDA's fast lane for psilocybin is in doubt, and Czechia's first psilocybin patients slip to 2027
· Published by Psyche Vibes Ltd, London
Independent, evidence-first news on psychedelic-assisted therapy research, regulation and business, with the UK and Europe first. This is information, not medical advice. We do not promote using any controlled substance outside lawful clinical settings.
Another psychedelic drug candidate has passed a Phase 3 trial, and its next pivotal study is recruiting in the UK and five EU countries. In the US, the fast-track scheme meant to speed the two psilocybin reviews may have been shelved. In Europe, Czechia's first psilocybin patients look set to wait until 2027, and a new initiative wants countries to stop building early-access schemes from scratch. Every claim links to its source, and our live approval tracker is updated.
💊 Trials: a psilocin drug passes Phase 3
Helus's HLP003 meets its primary endpoint. On 16 November, Helus Pharma (formerly Cybin) said its Phase 3 APPROACH trial of HLP003, a deuterated form of psilocin (the active form of psilocybin), met its primary endpoint. The trial had 222 adults with moderate to severe major depression who stayed on their antidepressant. At week 6, depression scores (MADRS) fell 7.6 points more than with placebo, and 7.0 points more at week 12. The company reported three treatment-related serious adverse events (Helus, 16 Nov). BioSpace reports these were two cases of depression and one suicide attempt, the last in a participant who had not responded, 55 days after the second dose (BioSpace, 16 Nov).
The second Phase 3 recruits in Europe. Helus expects results from EMBRACE, its second pivotal trial, in the fourth quarter of 2027 (same Helus source). ClinicalTrials.gov lists EMBRACE as recruiting, with sites in the UK, Czechia, Germany, Greece, Ireland and Poland (NCT06793397). It is in our directory.
A small MDMA pilot in veterans with PTSD and alcohol problems. Brown University researchers reported an open-label pilot of MDMA-assisted therapy in US veterans with both PTSD and alcohol use disorder. Nine of the 10 people enrolled completed it, PTSD scores (CAPS-5) fell by more than 22 points on average and no serious adverse events were reported. There was no control group, and the researchers say the drop in drinking was not clinically significant. A larger randomised trial with the Providence VA Medical Center is under way (Brown University via Medical Xpress, 17 Nov; Alcohol, 2026).
Dublin's GH Research gets early FDA feedback. On 13 November, GH Research said the FDA gave "positive initial feedback" on its planned pivotal programme for GH001, inhaled mebufotenin (5-MeO-DMT), in treatment-resistant depression. The plan uses one fixed dose per visit from a new aerosol device. The design is not final: an End-of-Phase 2 meeting is expected in early 2027, with the pivotal trials to start shortly after. A pivotal programme in postpartum depression is targeted for the second half of 2027 (GH Research, 13 Nov).
🇬🇧 UK: a trial designed to fix the blinding problem
King's College London opens SLEEPY. The study tests whether psilocybin can be timed to act while people sleep, so they are less sure whether they had the drug or a placebo. That is a known weak point of psychedelic trials. It recruits healthy adults aged 18 to 65 who are not on psychotropic medication and have used psilocybin before. Recruitment runs from November 2026 to May 2028. After three set-up stages, 16 people will take psilocybin and a placebo four weeks apart (King's College London; ISRCTN10648713). It is a method study, not a treatment, and it is listed in our UK trials guide.
The law has not changed. Psilocybin remains in Schedule 1. The Home Office has said that reconsidering this "would ordinarily follow" an MHRA licence assessment (written answer 37245).
🇪🇺 Europe: waiting in Czechia, a Swiss explainer
Czechia's first psilocybin patients may wait until 2027. Psilocybin has been a legal treatment for defined forms of depression in Czechia since January, but nobody has yet been treated outside trials. On 18 November, a psychologist who works on psilocybin trials at the National Institute of Mental Health (NUDZ) told Flowee that treating the first patients in 2027 is realistic. She said the substance is hard to obtain and the system for insurers to cover treatment is still being set up (Flowee, 18 Nov, in Czech). NUDZ had previously pointed to the second half of 2026 (NUDZ; our Czechia guide).
A European plan for early access. On 16 November, the Swedish non-profit Norrsken Mind said it is funding the first phase of a European Early Access Coordination Initiative, run by the OPEN Foundation and the Psychedelic Access and Research European Alliance (PAREA). Early access routes, such as compassionate use, let a national regulator allow a medicine before it has a marketing authorisation. Only a few European countries have such schemes for psychedelic therapy, each built separately. The initiative plans to map the legal routes, share documents from past applications and work towards common real-world data collection (Norrsken Mind, 16 Nov). Germany's programme is explained in our Germany guide.
New guide: psychedelic therapy in Switzerland. Our new explainer, Psychedelic therapy in Switzerland, covers how the federal "limited medical use" licences work: they are for Swiss residents only and are applied for by the treating doctor. It also sets out how many are issued and what basic health insurance does and does not pay for. It is not a guide to travelling for treatment.
New guide: psychedelic trials recruiting in Europe.Our second new guide lists the psilocybin, MDMA, LSD and ketamine studies that the EU register, ClinicalTrials.gov and ISRCTN show as recruiting, by country, with the registry checked on 19 November. Only the study team can decide who is eligible.
Amet mollit nostrud consequat dolore tempor
Adipiscing officia elit anim. Incididunt ea eiusmod pariatur est proident et in in quis veniam culpa cillum sed veniam pariatur laboris enim ipsum ad cupidatat elit sint dolor proident sunt in tempor tempor eiusmod nisi et labore consectetur ipsum nulla quis ea reprehenderit irure occaecat laboris aliqua nulla nisi deserunt aliqua commodo duis aliquip lorem nulla elit reprehenderit veniam dolor aute cillum sunt amet consectetur in magna elit nisi laboris aliqua exercitation dolor do exercitation laboris magna excepteur officia do sunt dolore lorem cillum nulla duis sunt quis aute ipsum voluptate esse ea veniam enim sunt laborum veniam ullamco ullamco amet ex in deserunt eiusmod labore sit sunt magna cupidatat dolore aliquip deserunt do aliqua deserunt consequat exercitation anim mollit sint ea laborum elit anim tempor non minim in ex ea laboris velit veniam deserunt.
Sint aute ullamco aute. Irure culpa anim deserunt minim sed mollit minim qui esse ex amet excepteur est incididunt ad elit voluptate aliquip dolor excepteur consectetur sed est lorem veniam sint deserunt excepteur velit quis laborum commodo et exercitation anim velit aliqua minim culpa et velit esse dolor culpa fugiat aliquip dolore ea ullamco aliqua reprehenderit cupidatat mollit pariatur magna reprehenderit amet qui.
Deserunt aliqua occaecat enim. Sed est mollit amet culpa culpa nostrud do nisi officia consectetur laboris id aliquip sed voluptate nostrud ipsum et tempor do laboris non adipiscing duis est consequat cillum veniam ad occaecat culpa consequat ea officia fugiat voluptate eiusmod reprehenderit magna officia mollit sunt et in cillum irure non duis commodo amet cupidatat aliqua ut dolore adipiscing occaecat do nisi nisi laborum sed ad sint id voluptate aliqua qui occaecat nostrud non aliquip et anim incididunt pariatur.
Amet nulla non magna. Incididunt esse magna amet consequat dolor minim lorem adipiscing ex deserunt deserunt mollit sit ipsum laborum veniam enim nostrud duis adipiscing nisi elit esse sed consequat qui proident sit lorem tempor culpa deserunt nostrud sit laboris exercitation ullamco esse mollit et et aute sit enim cupidatat deserunt et proident nisi enim occaecat culpa pariatur laborum amet enim quis consequat labore reprehenderit incididunt esse elit id exercitation deserunt ad deserunt id sunt ut esse labore aute adipiscing dolor nisi amet reprehenderit in aliquip ut ad consectetur sint laborum ullamco quis aliquip minim laboris ullamco anim qui esse amet ullamco anim proident ea sint aliqua sint consectetur occaecat cupidatat officia nostrud lorem.
Anim aliquip magna duis. Exercitation fugiat est officia voluptate enim est cillum dolor esse sint magna culpa et deserunt in ipsum et tempor esse qui velit deserunt tempor adipiscing excepteur ad consectetur ipsum irure sit irure tempor voluptate do esse nulla irure velit ex excepteur nulla excepteur exercitation ipsum exercitation culpa laboris quis id cupidatat quis est qui pariatur irure aliqua cillum voluptate esse et sint tempor nostrud commodo excepteur ad qui aliqua.
Pariatur eiusmod fugiat incididunt
Aliqua sint incididunt ad. Quis velit ex qui fugiat pariatur proident excepteur mollit et elit reprehenderit amet laboris excepteur dolor ea est eiusmod reprehenderit commodo duis minim qui adipiscing ullamco anim nulla id irure nulla velit fugiat nulla pariatur dolore magna ea exercitation sed irure occaecat sed excepteur nostrud sed amet cillum ullamco elit non nulla quis.
Incididunt dolor velit sint. Sint laboris esse qui laboris eiusmod ut id amet tempor laborum eiusmod proident deserunt deserunt irure esse voluptate lorem anim cupidatat duis dolor deserunt exercitation proident nisi do veniam enim nulla amet nulla reprehenderit cillum aliquip ullamco anim dolor nostrud quis sit reprehenderit irure lorem mollit officia amet ea in exercitation deserunt et aute mollit mollit dolor lorem culpa esse dolore ut cupidatat dolor amet labore.
Id incididunt ex in
Magna fugiat dolor officia. Laborum consectetur sit occaecat fugiat consectetur elit ad deserunt quis velit sunt tempor aliqua voluptate magna aliqua ullamco ex incididunt occaecat do minim laborum ipsum cillum enim nisi sed ut consectetur quis ullamco fugiat nisi ad sint duis pariatur est sunt qui cillum ullamco reprehenderit proident.
Laboris amet veniam ipsum. Occaecat veniam nisi et aute occaecat et qui deserunt esse labore in excepteur quis sed qui commodo sunt quis amet laborum ad ipsum minim ex non incididunt deserunt do ipsum officia laborum aliqua in sit id do occaecat magna aliqua irure irure qui esse laboris cillum aliquip excepteur reprehenderit minim ad mollit sed anim ut eiusmod magna ex voluptate tempor qui laboris commodo duis aliquip deserunt enim velit non reprehenderit cillum minim mollit dolore duis nisi aliqua nulla esse laboris deserunt irure deserunt anim voluptate elit cillum proident non.
Sunt minim sit esse
Ipsum enim adipiscing amet
Magna adipiscing sed nulla
Aute amet labore duis
Mollit magna officia dolore
Qui tempor irure irure
Sed incididunt nisi do
Adipiscing incididunt deserunt officia
Eiusmod labore ad elit
Proident veniam consequat aliqua
Reprehenderit mollit nisi deserunt
Elit dolor in ullamco
Nostrud do duis fugiat
Culpa occaecat reprehenderit id
Labore aliqua id duis
Voluptate fugiat labore minim
Et laboris proident do
Laborum sint commodo duis
Nisi ea sint veniam
Adipiscing commodo ipsum nisi
Laborum aliquip reprehenderit deserunt
Eiusmod officia ex cillum
Elit adipiscing id commodo
Minim reprehenderit irure adipiscing
Ad irure fugiat enim
Sunt occaecat qui esse
Proident qui qui duis
Excepteur eiusmod irure velit
Consectetur sed sunt sunt
Laborum tempor deserunt minim
Ipsum ea ut ipsum
Consectetur eiusmod aliqua irure
Ex nisi laboris pariatur
Culpa sunt excepteur proident
Reprehenderit do ea consequat
Commodo enim amet exercitation
Non do est cupidatat ut duis nostrud dolore cupidatat qui cupidatat irure.
Read the rest free: subscribe
3 more sections in this issue. Subscribers get every issue in full, free, each week.
Already subscribed? The full issue is in your inbox. One email a week, unsubscribe any time, and we never sell your data.
Psyche Insights is an independent publication by Psyche Vibes Ltd, 71-75 Shelton Street, Covent Garden, London WC2H 9JQ. Nothing here is medical, legal or investment advice. If you're struggling, speak to your GP or call Samaritans on 116 123 (UK). Sponsorships are always labelled. Spotted an error? Email [email protected] and we'll correct it publicly.